Macomics CRPC program (undisclosed target 2)

UNDISCLOSED-2 is a preclinical therapeutic program being developed by Macomics for the treatment of Castrate Resistant Prostate Cancer (CRPC). Macomics specializes in macrophage biology, focusing on the role of macrophages and other myeloid cells within the tumor microenvironment to develop novel cancer therapies. While the company's pipeline includes another CRPC program (UNDISCLOSED-1) that specifically targets Myeloid-Derived Suppressor Cells (MDSCs), the molecular target and mechanism of action for this particular program (UNDISCLOSED-2) have not yet been disclosed. The program is currently in the discovery phase, and Macomics utilizes a modality-agnostic approach that encompasses the development of both monoclonal antibodies and small molecule therapeutics.